Oct, 11 2017 12:48 JST

Source: Eisai

Small and Easy to Take, Just One Tablet per Dose Eisai to Launch "Onji-No-Megumi" for Improving Forgetfulness in Middle Age and Beyond

Supporting the Power of Memory

TOKYO, Oct, 11 2017 - (JCN Newswire) - Eisai Co., Ltd. will launch Onji-no-Megumi (category-3 OTC drug), a medicine for improving forgetfulness in middle age and beyond, on October 10 (Tuesday) at pharmacies and drugstores countrywide.

Onji-no-Megumi is a category-3 OTC drug containing onji extract, which is indicated for "improving forgetfulness in middle age and beyond." Onji is an herbal medicine made from the dried roots of Polygala tenuifolia, mainly known for improving functions related to memory. Onji-no-Megumi is miniaturized herbal formulation which only requires one tablet per dose. Additionally, the tablet is coated to suppress the distinctive bitter flavor of herbal medicines, making it easy to take.

Based on a survey carried out by Eisai, over 40% of people aged 40 and over experience episodes of forgetfulness, such as "being unable to recall the name of a person or thing" or "mentioning the same thing over and over", and this makes them feel uneasy. However, at present, forgetfulness is considered to be natural consequence of aging and is thus difficult to treat. Onji-no-Megumi can be used to improve the memory functions of middle aged and older people who are concerned about forgetfulness.

Eisai is proactively engaged in spreading awareness of dementia and forgetfulness as well as in community building activities to support collaboration between stakeholders such as government, medical and care facilities.

Through the delivery of this product, Eisai seeks to further contribute to increasing the benefits provided to those who are concerned about forgetfulness, even in the area of self-medication.

http://www.acnnewswire.com/topimg/Low_EisaiOnjinoMegumi.jpg

About herbal medicine Onji

Onji is an herbal medicine made from the dried roots of Polygala tenuifolia. The name "onji" was recorded in the Compendium of Materia Medica, a classic Chinese text on medicinal plants, where it was named for its benefits of "increasing wisdom and strengthening will" and its powerful medicinal effect on the neuropsychiatric system. It was also found in the Shennong Ben Cao Jing, the oldest known Chinese medical text, and has historically been used in kamiuntanto (gallbladder warming decoctions), kamikihito (spleen restoration decoctions) and ninjinyoeito (ginseng nutrition decoctions).


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: HealthCare

Copyright ©2017 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Multimedia


Onji-no-Megumi (category-3 OTC drug)
 

Related Press Release


Eisai: Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25mg in Japan
October 13 2017 09:48 JST
 
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America
October 04 2017 09:49 JST
 
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan
October 03 2017 14:11 JST
 
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting
September 29 2017 15:12 JST
 
Eisai: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA
September 27 2017 12:25 JST
 
Eisai: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis
September 22 2017 15:46 JST
 
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC
September 22 2017 09:56 JST
 
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference
September 19 2017 09:01 JST
 
Eisai to Launch New "Etak Antimicrobial Spray Alpha" Containing Long-Acting Antimicrobial Agent Etak
September 13 2017 13:25 JST
 
Eisai and Mamorio to Jointly Launch "Me-Mamorio" Tracking Tool to Support People with Dementia and Seniors Going Out
September 12 2017 23:06 JST
 
More Press release >>

Latest Press Release


More Latest Release >>